SECOND AMENDED AND RESTATED CONTINGENT LICENSE AGREEMENTContingent License Agreement • September 4th, 2007 • Matritech Inc/De/ • In vitro & in vivo diagnostic substances • Delaware
Contract Type FiledSeptember 4th, 2007 Company Industry JurisdictionThis SECOND AMENDED AND RESTATED CONTINGENT LICENSE AGREEMENT (this “Agreement”) is made as of the 30th day of August, 2007 (the “Effective Date”), by and among MATRITECH, INC. a corporation organized under the laws of the State of Delaware (the “Licensor”), and SDS CAPITAL GROUP SPC, LTD. (the “Licensee”), as collateral agent for the holders (the “Holders”) of the Series A Notes, Series B Notes and Series C Notes (as defined below) (in such capacity, the “Collateral Agent”).
AMENDED AND RESTATED CONTINGENT LICENSE AGREEMENTContingent License Agreement • January 24th, 2007 • Matritech Inc/De/ • In vitro & in vivo diagnostic substances • Delaware
Contract Type FiledJanuary 24th, 2007 Company Industry JurisdictionThis AMENDED AND RESTATED CONTINGENT LICENSE AGREEMENT (this “Agreement”) is made as of the 22nd day of January, 2007 (the “Effective Date”), by and among MATRITECH, INC. a corporation organized under the laws of the State of Delaware (the “Licensor”), and SDS CAPITAL GROUP SPC, LTD. (the “Licensee”), as collateral agent for the holders (the “Holders”) of the Series A Notes and the Series B Notes (as defined below) (in such capacity, the “Collateral Agent”).